Liposomal irinotecan plus bevacizumab for irinotecan-refractory colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new version of the chemotherapy drug irinotecan (called liposomal irinotecan) combined with bevacizumab, a targeted therapy, for people with colorectal cancer that has spread and has stopped responding to irinotecan. The goal is to see if this combination can control the tumor better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- Your colorectal cancer has spread to other parts of the body and cannot be removed with surgery.
- You have already taken irinotecan and your cancer got worse while on it or within 3 months after stopping.
- You are able to perform daily activities (you are up and about) and have a life expectancy of at least 3 months.
- Your blood counts, liver, and kidney function meet certain safety levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new form of chemotherapy (liposomal irinotecan) combined with two standard drugs (5-FU and leucovorin) and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this combination shrinks tumors and helps people live longer.
This trial tests a combination of liposomal irinotecan, two chemotherapy drugs (leucovorin and 5-fluorouracil), and bevacizumab as a second-line treatment for people with colorectal cancer that has spread and cannot be removed by surgery.
This trial is testing a combination of three drugs (liposomal irinotecan, capecitabine, and bevacizumab) for people with metastatic colorectal cancer whose first-line treatment failed. The goal is to see if this combo works better as a second option.
This trial tests a new drug combined with a standard treatment for advanced colorectal cancer that has not responded to earlier therapies. It aims to see if the combination can help slow the cancer's growth.
This trial tests a new form of the chemotherapy drug irinotecan (called irinotecan liposome) combined with two other chemo drugs and a targeted therapy (bevacizumab) for people with advanced colorectal cancer that has already been treated with oxaliplatin. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
Hear when a new Colorectal cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.